Management of antihypertensive drugs in three European countries

Journal of Hypertension

Volumn 27, Issue 9, 2009, Pages 1917-1922

  Nicotra, Federica ^a   Wettermark, Björn ^b   Sturkenboom, Miriam C ^c   Parodi, Andrea ^a   Bellocco, Rino ^a,d   Ekbom, Anders ^e   Merlino, Luca ^f   Leimanis, Andrejs ^g   Mancia, Giuseppe ^a   Fored, Michael ^e,g   Corrao, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Network for Pharmacoepidemiology Foundation   (Sweden)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Operative Unit of Territorial Health Services   (Italy)

^g CENTRE FOR EPIDEMIOLOGY   (Sweden)

Author keywords

Antihypertensive agents; Competing risks; Cumulative incidence; Drug compliance; Record linkage; Therapy changing; Treatment discontinuation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ORGANIC NITRATE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIBLIOGRAPHIC DATABASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SWEDEN; TREATMENT DURATION;

EID: 73249118683     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832d4692     Document Type: Article

References (26)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
2. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22:11-19. (Pubitemid 38293521)
3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
4. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001 : systematic analysis of population health data. Lancet 2006; 367:1747-1757.
5. Stephenson J. Noncompliance may cause half of antihypertensive drug 'failures'. JAMA 1999; 282:313-314.
6. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich) 2008; 10:20-26.
7. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003; 326:1427.
8. Morgan TO, Anderson AI, Maclnnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001 ; 14:241-324.
9. Ruilope LM, Burnier M, Muszbek N, Brown RE, Keskinaslan A, Ferber P, Harms G. Public health value of fixed-does combinations in hypertension. Blood Press Suppl 2008; 1:5-14.
10. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly treated patients: a population-based study in Italy. J Hypertens 2008; 26:819-824. (Pubitemid 351354932)
11. Wettermark B, Hammar N, Fored MC, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register. Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16:726-735. (Pubitemid 47180362)
12. Erkens JA, Panneman MmJ, Klungel OH, van den Boom G, Prescott MF, Herings RMC. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14:795-803.
13. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23:2093-2100. (Pubitemid 41830406)
14. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24:1193-1200. (Pubitemid 43772328)
15. Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, Kotchen T, Mouton C, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004; 292:2849-2859. (Pubitemid 39628232)
16. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17. (Pubitemid 38031904)
17. Benetos A, Thomas F, Bean KE, Guize L Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21:1635-1640. (Pubitemid 37076345)
18. Redon J, Cea-Calvo L, Lozano JV, Marti-Canales JC, Llisterri JL, Aznar J, Gonzalez-Esteban J, PREV-ICTUS Study. Differences in blood pressure control and stroke mortality across Spain: the Prevencion de Riesgo de Ictus (PREV-ICTUS) study. Hypertension 2007; 49:799-805. (Pubitemid 351664224)
19. Greving JP, Denig P, van der Veen WJ, Beltman FW, Sturkenboom MC, de Zeeuw D, Haaijer-Ruskamp FM. Does comorbidity explain trends in prescribing of newer antihypertensive agents? J Hypertens 2004; 22:2015-2209.
20. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006; 40:15-20.
21. Padiyara RS, D'Souza JJ. Quantifying the opportunity for pharmacists to improve management of hypertension in a primary care medical clinic. J Manag Care Pharm 2008; 14:322-323.
22. Lindgren S, Bass AS, Briscoe R, Bruse K, Friedrichs GS, Kallman MJ, et al. Benchmarking Safety Pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods 2008; 58:99-109.
23. Lee AK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. A randomized controlled trial. JAMA 2006; 296:2563-2571.
24. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-ofuse packaging improve adherence? A systematic review. Bull World Health Organ 2004; 82:935-939. (Pubitemid 40065162)
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., the National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2004; 42:1206-1252.
26. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology, Third Edition New York: John Wiley & Sons; 2000. pp. 219-222.